253 related articles for article (PubMed ID: 28806395)
21. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
22. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor.
Liu KC; Yo YT; Huang RL; Wang YC; Liao YP; Huang TS; Chao TK; Lin CK; Weng SJ; Ma KH; Chang CC; Yu MH; Lai HC
Oncotarget; 2013 Dec; 4(12):2366-82. PubMed ID: 24280306
[TBL] [Abstract][Full Text] [Related]
24. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
[TBL] [Abstract][Full Text] [Related]
25. RAD6 promotes chemoresistance in ovarian cancer.
Clark DW; Mani C; Palle K
Mol Cell Oncol; 2018; 5(1):e1392403. PubMed ID: 29404391
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
28. In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.
Berkel C; Cacan E
Cell Biol Int; 2020 Aug; 44(8):1598-1605. PubMed ID: 32208526
[TBL] [Abstract][Full Text] [Related]
29. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
30. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer.
Matsushita Y; Yokoyama Y; Yoshida H; Osawa Y; Mizunuma M; Shigeto T; Futagami M; Imaizumi T; Mizunuma H
J Ovarian Res; 2014 Nov; 7():107. PubMed ID: 25424877
[TBL] [Abstract][Full Text] [Related]
31. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
[TBL] [Abstract][Full Text] [Related]
33. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitin-conjugating enzyme 9 promotes epithelial ovarian cancer cell proliferation in vitro.
Dong M; Pang X; Xu Y; Wen F; Zhang Y
Int J Mol Sci; 2013 May; 14(6):11061-71. PubMed ID: 23708104
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
[TBL] [Abstract][Full Text] [Related]
36. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
37. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
Chen J; Wang J; Zhang Y; Chen D; Yang C; Kai C; Wang X; Shi F; Dou J
J Biosci Bioeng; 2014 Aug; 118(2):214-22. PubMed ID: 24684961
[TBL] [Abstract][Full Text] [Related]
38. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
39. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
[TBL] [Abstract][Full Text] [Related]
40. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
